Pays: Canada
Langue: anglais
Source: Health Canada
ALPRAZOLAM
MYLAN PHARMACEUTICALS ULC
N05BA12
ALPRAZOLAM
0.25MG
TABLET
ALPRAZOLAM 0.25MG
ORAL
100/1000
Targeted (CDSA IV)
BENZODIAZEPINES
Active ingredient group (AIG) number: 0115008001; AHFS:
CANCELLED POST MARKET
2017-12-12
PRODUCT MONOGRAPH MYLAN-ALPRAZOLAM ALPRAZOLAM TABLETS, USP 0.25 MG, 0.5 MG, 1 MG, AND 2 MG ANXIOLYTIC - ANTIPANIC Mylan Pharmaceuticals ULC Date of Revision: June 6, 2019 85 Advance Road, Etobicoke, Ontario M8Z 2S6 Control No.: 228228 IMPORTANT : PLEASE READ 2 PART I: HEALTH PROFESSIONAL INFORMATION ................................................................................................ 3 SUMMARY PRODUCT INFORMATION ............................................................................................................................ 3 INDICATIONS AND CLINICAL USE .................................................................................................................................. 3 CONTRAINDICATIONS ...................................................................................................................................................... 5 WARNINGS AND PRECAUTIONS ..................................................................................................................................... 6 ADVERSE REACTIONS ..................................................................................................................................................... 13 DRUG INTERACTIONS ..................................................................................................................................................... 17 DOSAGE AND ADMINISTRATION .................................................................................................................................. 20 OVERDOSAGE ................................................................................................................................................................... 21 ACTION AND CLINICAL PHARMACOLOGY ................................................................................................................ 22 STABILITY AND STORAGE RECOMMENDATIONS .................................................................................................... 23 DOSAGE FORMS, COMPOSITION AN Lire le document complet